CENTRI Cellular Sentries for the Interception of Colorectal Tumorigenesis in Lynch Syndrome
- Coordinator
- Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Spain
- Runs
- 1 January 2027 to 31 December 2031
- Status
- Running
- EU funding
- €1.8m
- Total cost
- €1.8m
- Partners
- 2 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101302646
What the project is doing
In the project's own words, from its summary on CORDIS.
Our understanding of how the immune system shapes human tumorigenesis comes mainly from invasive cancers that have escaped immune control. Mice cannot fully reproduce this process, leaving the earliest phases of human immunosurveillance unresolved. To address this gap, I established systemic biosampling across tumorigenesis in patients with Lynch syndrome (LS), a hereditary cancer predisposition and unique model for immunosurveillance.
During their lifespans, LS patients accumulate immunogenic mismatch repair-deficient (MMRd) progenitor lesions leading to invasive cancers frequently missed by screening due to their unusually rapid outgrowth. My central hypothesis is this rapid cancer onset is enabled by early systemic immune dysfunction resulting from chronic antigen exposure. To resolve this, CENTRI will define when systemic immunosurveillance emerges and fails in LS and how this collapse relates to tissue-level escape thereby identifying windows for optimal cancer interception.
CENTRI pursues three objectives to realize this aim: First (SO1), we will develop a computational framework to reconstruct the onset and evolution of systemic immunosurveillance from blood single-cell data. This will be augmented by a new in-patient antigen perturbation assay which will allow us for the first time to phenotypically characterise neoantigen-specific T cells in cancer-free patients. Second (SO2), we will define the co-evolution of systemic and tissue-level immune escape by mapping neoantigen-reactive T cells and Natural Killer (NK) cells from blood to colorectal cancer precursors.
Third (SO3), we will functionally test T and NK cell surveillance across tumorigenesis stages using avatar mice engrafted with patient-derived immune cells and MMRd colorectal cancers. Together, CENTRI promises to delineate the emergence and failure of human immunosurveillance, advance our quantitative understanding of systemic immunity, and provide the basis for immune-based cancer interception.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Coordinator |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI